The turnover kinetics of major histocompatibility complex peptides of human cancer cells.
about
DRiPs solidify: progress in understanding endogenous MHC class I antigen processingGlobal analysis of cellular protein translation by pulsed SILACMetabolic turnover of synaptic proteins: kinetics, interdependencies and implications for synaptic maintenanceThe Human Immunopeptidome Project, a suggestion for yet another postgenome next big thingMass Spectrometry of Human Leukocyte Antigen Class I Peptidomes Reveals Strong Effects of Protein Abundance and Turnover on Antigen PresentationThe contributions of mass spectrometry to understanding of immune recognition by T lymphocytes.Systematic characterisation of cellular localisation and expression profiles of proteins containing MHC ligands.Advanced identification of proteins in uncharacterized proteomes by pulsed in vivo stable isotope labeling-based mass spectrometryRetargeting NK92 cells using an HLA-A2-restricted, EBNA3C-specific chimeric antigen receptor.The use of mouse models to better understand mechanisms of autoimmunity and toleranceProteome sampling by the HLA class I antigen processing pathwaySoluble plasma HLA peptidome as a potential source for cancer biomarkersKinetics of antigen expression and epitope presentation during virus infection.The MHC I immunopeptidome conveys to the cell surface an integrative view of cellular regulation.A quantitative spatial proteomics analysis of proteome turnover in human cells.New lane in the information highway: alternative reading frame peptides elicit T cells with potent antiretrovirus activity.The MHC class I peptide repertoire is molded by the transcriptome.Modeling the Treatment of Glioblastoma Multiforme and Cancer Stem Cells with Ordinary Differential EquationsHuman Leukocyte Antigen-Presented Macrophage Migration Inhibitory Factor Is a Surface Biomarker and Potential Therapeutic Target for Ovarian Cancer.Analysis of Major Histocompatibility Complex (MHC) Immunopeptidomes Using Mass Spectrometry.Contribution of mass spectrometry-based proteomics to immunology.Immunoproteasome deficiency is a feature of non-small cell lung cancer with a mesenchymal phenotype and is associated with a poor outcome.Amsterdamming DRiPs.Sampling From the Proteome to the Human Leukocyte Antigen-DR (HLA-DR) Ligandome Proceeds Via High SpecificityIdentification of T-cell epitopes for cancer immunotherapy.Quantitative proteomic profiling of host-pathogen interactions: the macrophage response to Mycobacterium tuberculosis lipids.Method revealing bacterial cell-wall architecture by time-dependent isotope labeling and quantitative liquid chromatography/mass spectrometryStable isotope pulse-chase monitored by quantitative mass spectrometry applied to E. coli 30S ribosome assembly kinetics.Chemical tools for temporally and spatially resolved mass spectrometry-based proteomics.Translating DRiPs: MHC class I immunosurveillance of pathogens and tumors.Re-examining class-I presentation and the DRiP hypothesisImpact of genomic polymorphisms on the repertoire of human MHC class I-associated peptides.The nature and extent of contributions by defective ribosome products to the HLA peptidome.Insights into MHC class I antigen processing gained from large-scale analysis of class I ligands.The expanding field of SILAC.Quantitative mass spectrometry in proteomics: critical review update from 2007 to the present.State of the art of 2D DIGE.Quantitative proteomics using SILAC: Principles, applications, and developments.Mass Spectrometry Profiling of HLA-Associated Peptidomes in Mono-allelic Cells Enables More Accurate Epitope Prediction.The human leukocyte antigen-presented ligandome of B lymphocytes.
P2860
Q27006750-72BAE6FB-A753-41C0-A594-F441AA9D192AQ28302639-605CFF1D-A5FC-47E7-B626-F1EFFC071FDCQ28487557-27E523D3-A3EE-42EF-BFC7-70F73B296E37Q28743282-6399D668-9DA9-4781-BF85-F9A75DB6BB06Q30002365-68BB800C-FB28-47C9-96A9-0CF9A5823B83Q30444065-C02AA532-D198-4EFE-BB24-697AB121D978Q33510342-F3F49DC7-FDBF-41D0-97D5-0B765EEB4BD7Q33883016-85273A11-49CB-4718-AC9C-30E9990CF013Q34042430-28268C6C-8806-40A0-B6EB-58080484C334Q34208888-5D96BECA-B617-4AA8-89DF-582DFB6A0E3BQ34276972-71AD9945-6B40-4DF7-90B9-365163607BD9Q34279102-ACD195D3-0CE2-42AF-9520-42ED7C7DB194Q34574829-8096AE13-84A1-4C1B-91BD-1D0E6ACC9E0FQ35458694-7F302677-A0B4-4BDD-8104-66FE08F175F9Q35863277-70A53080-35B4-4074-8BF3-FCBE5CA72A14Q36229113-0B31C0D6-A0B9-4B58-AF58-C3C9D01DF967Q36509857-6B396BDE-0835-4653-BE9C-3148EAAD18E1Q36555910-95F7334A-F2A3-456A-959E-950869751164Q36563742-4B981BD3-06EA-493A-81A6-55CF48A71065Q36604367-B0DD7E7E-624C-456B-81E6-6413EE4FBBFBQ36689114-E9772CCD-2FAC-41F0-8073-9342612B1528Q36710603-A218A514-66AA-402F-82A4-0156C0EFAA39Q36724559-E700D37F-8EFE-4311-B742-DA07F70DA36EQ36778316-419744EF-1C8E-47E9-A39F-50663148E9CFQ36870592-2CCF69DB-B6C6-4F52-B548-4AAD0E7EDC05Q37127448-DBCDBF83-581A-494C-8D65-F99C55B8D8E8Q37274197-33D43D8B-DF96-4FE6-AC8D-51D52B0C4245Q37366838-4E99B2A9-7AF4-4865-8B9C-CE2878D77B4CQ37585697-BD5E6892-2D86-431D-BACA-4652137D83D6Q37644973-25794981-E659-4E39-951A-EC7A6D72C10DQ37702916-B4F8E73F-6A7F-4BEB-BD46-3D086C47CECBQ37718264-F5F62E4F-92F8-44B6-BA96-905B210CAA8EQ37725183-B4E9878A-F866-4E80-8F6A-A105FAF24CE4Q37851048-BBB75E31-0428-41DF-B65D-82506597540CQ38004824-4025237C-4E3B-478C-8DD9-1819D0087C70Q38024637-B79479BF-6002-4F88-A234-C7C57E09DE44Q38268593-978D95FC-B1FF-4E4C-81C6-50EEECA440B3Q38533946-F340EDA1-C558-4D36-A920-14B261346980Q38947679-FE838D45-ABF2-49BF-A486-5AD7DF5D59ECQ39182194-63CB0317-EF48-497E-8B9E-CE6EAAE1EC51
P2860
The turnover kinetics of major histocompatibility complex peptides of human cancer cells.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
The turnover kinetics of major histocompatibility complex peptides of human cancer cells.
@en
The turnover kinetics of major histocompatibility complex peptides of human cancer cells.
@nl
type
label
The turnover kinetics of major histocompatibility complex peptides of human cancer cells.
@en
The turnover kinetics of major histocompatibility complex peptides of human cancer cells.
@nl
prefLabel
The turnover kinetics of major histocompatibility complex peptides of human cancer cells.
@en
The turnover kinetics of major histocompatibility complex peptides of human cancer cells.
@nl
P2093
P2860
P1476
The turnover kinetics of major histocompatibility complex peptides of human cancer cells
@en
P2093
Eilon Barnea
Elena Milner
P2860
P304
P356
10.1074/MCP.M500241-MCP200
P50
P577
2005-11-04T00:00:00Z